This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

The CDC's vaccine advisory committee is set to meet for the first time since HHS Secretary Robert F. Kennedy Jr. dismissed ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

A virus that once filled pediatric hospital beds and terrified new parents is finally being pushed back—before babies are ...

Studies have found important benefits from a newer vaccine and enhanced versions of older ones, and one vaccine may confer a ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

On Wednesday, the eight new members of the CDC’s Advisory Committee on Immunization Practices will begin a 2-day meeting in ...